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Background: Complications following spontaneous or induced abortion are a major cause of maternal morbidity.
To manage these complications, post-abortion care (PAC) services should be readily available and easy to access.
Standard PAC treatment includes surgical interventions that are highly effective but require surgical providers and
medical centers that have the necessary space and equipment. Misoprostol has been shown to be an effective
alternative to surgical evacuation and can be offered by lower level clinicians. This study sought to assess whether
400 mcg sublingual misoprostol could effectively evacuate the uterus after incomplete abortion and to confirm its
applicability for use at lower level settings.
Methods: All women presenting with incomplete abortion at one of three hospitals in Vietnam were enrolled.
Providers were not asked to record if the abortion was spontaneous or induced. It is likely that all were spontaneous
given the legal status and easy access to abortion services in Vietnam. Participants were given 400 mcg sublingual
misoprostol and instructed to hold the pills under their tongue for 30 minutes and then swallow any remaining
fragments. They were then asked to return one week later to confirm their clinical status. Study clinicians were
instructed to confirm a complete expulsion clinically. All women were asked to complete a questionnaire regarding
satisfaction with the treatment.
Results: Three hundred and two women were enrolled between September 2009 and May 2010. Almost all
participants (96.3%) had successful completions using a single dose of 400 mcg misoprostol. The majority of women
(87.2%) found the side effects to be tolerable or easily tolerable. Most women (84.3%) were satisfied or very satisfied
with the treatment they received; only one was dissatisfied (0.3%). Nine out of ten women would select this method
again and recommend it to a friend (91.0% and 90.0%, respectively).
Conclusions: This study confirms that 400 mcg sublingual misoprostol effectively evacuates the uterus for most
women experiencing incomplete abortion. The high levels of satisfaction and side effect tolerability also attest to the
ease of use of this method. From these data and given the international consensus around the effectiveness of
misoprostol for incomplete abortion care, it seems timely that use of the drug for this indication be widely expanded
both throughout Vietnam and wherever access to abortion care is limited.
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Complications following spontaneous or induced abor-
tion are a major cause of maternal morbidity [1]. To
manage these complications, post-abortion care (PAC)
services should be readily available and easy to access. In
Vietnam, incomplete abortion accounts for a large per-
centage of emergency room visits and medical interven-
tions, contributing greatly to the cost and staffing burden
of hospitals.
Standard care for abortion complications includes sur-
gical interventions, such as vacuum aspiration (manual
or electric) or dilatation and curettage (D&C). While
highly effective, these methods require trained surgical
providers and medical centers that have the necessary
space and equipment. Misoprostol (600 mcg given orally
or 400 mcg sublingually) has been shown to be an effect-
ive alternative to surgical treatment with similarly high
rates of satisfaction [2-9]. The medication method can
be offered by clinicians without surgical skills thus poten-
tially increasing access for women while also reducing
hospital costs and freeing up the time of over-burdened
higher level providers [10,11].
Women could benefit greatly from a non-invasive
treatment option for incomplete abortion. While safe
surgical services are becoming more widespread, there is
still a risk of complications, such as uterine adhesion,
from these procedures. In addition, as seen in the in-
duced abortion literature, many women prefer medical
over surgical treatment when given the option [12-14].
Introducing misoprostol treatment for incomplete abor-
tion is an important step towards improving care for
women experiencing abortion complications.
In this study, we investigated 400 mcg sublingual mi-
soprostol as first line care for incomplete abortion at
three hospitals in Vietnam. We hypothesized that dem-
onstration of the effectiveness, safety and satisfaction
with this non-surgical approach in a hospital setting
would provide sufficient evidence to support its intro-
duction at lower levels of the health care sector and in
so doing, contribute to task-shifting efforts aimed at
empowering non-physician providers to manage certain
medical conditions.
Methods
This open-label study enrolled women presenting with
incomplete abortion at one of three hospitals in Vietnam:
Tu Du Hospital, Ho Chi Minh City; National OBGYN
Hospital, Hanoi; or Cu Chi District Hospital, Ho Chi
Minh City. Incomplete abortion was diagnosed with an
open cervical os and vaginal bleeding at time of presenta-
tion for services. In addition, if ultrasound was used, the
provider identified 1) thickened endometrial stripe (i.e.,
greater than 8 mm) and 2) substantial debris in the
uterus. Providers were not asked to note if the abortionwas spontaneous or induced although the presumption
was that all were spontaneous given the legal status and
easy access to abortion services throughout Vietnam.
Additional eligibility criteria included uterine size no lar-
ger than 12 weeks gestation, no signs of severe infection,
no hemodynamic disturbances, no contraindications to
misoprostol, living or working within one hour of the
study hospital, general good health, and willingness to
provide contact information and return for follow-up
care. IRB approval was granted by the three participating
hospitals and all participants gave informed consent prior
to enrollment using a form developed in Vietnamese.
All participants were given 2 tablets of 200 mcg mi-
soprostol (total = 400 mcg) sublingual misoprostol
(Cytotec, Pfizer, USA) and instructed to hold the pills
under their tongue for 30 minutes and then swallow
any remaining fragments. Women could leave the hos-
pital immediately after the tablets were administered.
Paracetamol was offered to all participants to help with
pain management.
Participants were asked to return to the hospital one
week later to confirm their clinical status. Study clini-
cians were instructed to confirm a complete expulsion
clinically and to use ultrasound only when deemed abso-
lutely necessary; however, the IRB at one hospital re-
quired that ultrasound be performed at follow-up on all
participants at that site. As it is generally standard prac-
tice to use clinical symptoms with or without ultrasound
to evaluate success, this was considered an appropriate
means to confirm abortion status [15]. If there was con-
tinued heavy bleeding, an enlarged uterus, or any suspi-
cion of an ectopic pregnancy, the woman was referred
for ultrasound and follow-up care as needed. In the
event of continued incomplete abortion, participants
were offered either an additional dose of misoprostol,
immediate surgical completion, or to simply wait and
return for an extended follow-up one week later. If,
after the second follow-up visit, the abortion was not
complete, a surgical completion using manual or elec-
trical aspiration was performed. After the procedure,
all women were asked to respond to a set of questions
regarding their satisfaction with the treatment. Study
participants received treatment at no cost and were
compensated 170,000 VND (approximately 10 USD)
for their travel to the hospital.
The study sought to assess whether 400 mcg sublin-
gual misoprostol could effectively evacuate the uterus
after incomplete abortion and to understand if the
method could be used with limited ultrasound to con-
firm its applicability for use at lower level settings. In
addition, the side effects of the sublingual route were
assessed. Data entry and analysis were done with SPSS
version 13 (IBM, Armonk, NY) and STATA version 11







Outcome, side-effect, & acceptability analysis
n=300
Figure 1 Participant flowchart.
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fects, and women’s satisfaction with the treatment were
collected and analyzed by frequency and/or means.
The study was not powered to look at any pre-set dif-
ferences, but rather to provide sufficient evidence that
the method could work in this setting. From this, in
discussion with local colleagues, we determined that a
sample size of 300 participants would be reasonable to
provide sufficient evidence to bolster support for the
use of misoprostol for incomplete abortion manage-
ment in this setting.
Results
Three hundred and two women were enrolled between
September 2009 and May 2010. The average age of par-
ticipants was 28 years, and most women had completed
secondary education (41.6%) (Table 1). The women had,
on average, one full term pregnancy and one abortion.
Two women were lost to follow-up before study comple-
tion and are therefore only included in the demographic
analyses. Figure 1 outlines the flow of participants in
the trial.
The vast majority of participants (96.3%) had suc-
cessful completions using a single dose of 400 mcg
misoprostol (Table 2). There were no significant dif-
ferences in success rates by site. Reasons for having
surgical interventions included incomplete abortion at
follow-up (n = 2), medical necessity (n = 2), woman’s
request (n = 6), and ectopic pregnancy (n = 1). Of
the two women with incomplete abortions, one had
surgical intervention after follow-up and the other
after extended follow-up. The participant with ectopic
pregnancy was not identified by ultrasound at enroll-
ment and only had her ectopic confirmed after a sec-
ond ultrasound at follow-up when intra-abdominal
bleeding was identified.
Most women (83.3%) reported that they felt that the
abortion was complete at the time of their one-weekTable 1 Participants’ characteristics
n = 302
Age in years: mean ± SD (range) 28 ± 6.0 (15–46)a
Education level completed: % (n)
Less than primary 3.4 (10/298)
Primary 37.9 (113/298)
Secondary 41.6 (124/298)
Completed secondary education or higher 17.1 (51/298)
Parity: median; mean ± SD (range) 1; 1.2 ± 1.3 (0–7)b
Number of previous abortions: median;
mean ± SD (range)
0; 0.5 ± 0.9 (0–6)c
a n = 300.
bn = 286.
cn = 275.follow-up appointment. (Of these 249 women, all but
one was correct; data not shown). Ultrasound was used
to evaluate success for almost three-quarters (71.7%) of
participants, although this varied by site. As mandated
by one hospital, 100% of participants had post-treatment
ultrasound. At the two hospitals where use of ultrasound
at follow-up was optional, its use ranged from 25.8%
to 87.9%. One in five women made an unscheduled
visit or phone call to the hospital (18.3% and 21.0%,
respectively).
Nausea and chills were the most commonly reported
side effects (Table 3). Indeed, slightly over half of the
participants (57.7%) reported nausea, while approxi-
mately one-third (37.3%) reported chills. Other reported
side effects included diarrhea (11.3%), vomiting (7.0%),
and fever (3.7%). A large majority of women (87.2%)
found the side effects to be tolerable or easily tolerable.Table 2 Results
n = 300
Success: % (n)
Complete abortion 96.3 (289)
Surgical intervention 3.7 (11)
Incomplete abortion at follow-up 0.7 (2)
Medically necessary 0.7 (2)
Woman’s request 2.0 (6)
Ectopic pregnancy 0.3 (1)
Woman thought abortion was complete at follow-up: % (n) 83.3 (249/299)
Ultrasound used to evaluate success at follow-up: % (n) 71.7 (213/297)
Women who made an unscheduled visit: % (n) 18.3 (55/300)
Women who called the provider: % (n) 21.0 (63/300)







Tolerability of side effects
No side effects 12.1 (36/298)
Easily tolerable or tolerable 87.2 (260/298)
Bad or very bad 0.7 (2/298)
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the treatment they received; only one woman was dissatis-
fied (0.3%) (Table 4). Nine out of ten women would select
this method again and recommend it to a friend (91.0%
and 90.0%, respectively). Among the women who had pre-
viously had a surgical evacuation for incomplete abortion
(n = 94), over two-thirds (70.9%) found the misoprostol
method to be the same or better.
Discussion
These results confirm that 400 mcg sublingual misoprostol
effectively evacuates the uterus for most women experien-
cing incomplete abortion [7]. The high level of satisfaction
and overall tolerability of the side effects also attests to the
ease of use of this method. International momentum and
consensus around the drug’s utility for this indication hasTable 4 Overall acceptability of treatment: % (n)
n = 300
Satisfaction with treatment
Satisfactory or very satisfactory 84.3 (253)
Neither satisfactory nor unsatisfactory 15.3 (46)
Unsatisfactory or very unsatisfactory 0.3 (1)
Would select this method again, if needed
Yes 91.0 (273)
Unsure 9.0 (27)









a 94 women reported having a past surgical evacuation for this indication.grown stemming in part from misoprostol’s inclusion on
the WHO’s essential medicines list (EML) for this indica-
tion [16]. The drug is now labeled specifically for incom-
plete abortion in certain jurisdictions [17] and, in 2012, it
was listed as a priority life-saving medicine for women and
children [18].
Although a proportion of women did receive ultra-
sound confirmation of their incomplete abortion, it does
appear that its use was not essential. The ability to suc-
cessfully treat this condition without ultrasound has been
previously documented in other research on this topic
[15,19,20]. Indeed, only women with symptoms such as
heavy bleeding or signs of infection should require add-
itional care; however, ultrasound is typically used to iden-
tify retained products that will eventually expel on their
own. Some providers feel that ultrasound is essential to
identify possible ectopic pregnancy, even in the event of
suspected incomplete abortion. In this study, there was
one ectopic pregnancy diagnosed at follow-up by ultra-
sound. Interestingly, this event occurred at the one hos-
pital where ultrasound confirmation of incomplete
abortion status prior to enrollment was mandated. Yet,
the ultrasound assessment missed the ectopic pregnancy
at enrollment and the woman’s status was later recog-
nized upon repeat ultrasound at the follow-up exam.
Clinical diagnosis of ectopic pregnancy is possible by care-
ful examination including discussion of clinical symptoms
with the woman. Although ultrasound is helpful, this
study shows that simply mandating its use will not iden-
tify 100% of such events. Additional training might help
to reassure clinicians that the outcome can often be
ascertained with careful clinical exam.
This study has several limitations. For one, the sample
size is quite small and the study was not powered. Instead,
we sought to simply demonstrate the effectiveness of this
already proven method in a different country setting. Sec-
ondly, we had hoped that ultrasound would not be used at
all so as to best demonstrate how the method can be of-
fered without ultrasound. We were unable to achieve this
due to the reluctance of one hospital’s ethical committee to
approve the protocol without stipulating universal use of
ultrasound. Furthermore, as we had feared, given the ease
of access to ultrasound at the three facilities selected, it
was difficult for providers to shift attitudes and not use the
technology that was available to them. In spite of this, the
fact that one facility did only use ultrasound for a quarter
of its participants shows that the method can be provided
safely and effectively without this technology. It will take
more time to change attitudes about its use. Fortunately,
the use of ultrasound did not lead to an increase in inter-
ventions and the method’s effectiveness was demonstrated
at all three hospitals.
As is generally the practice at ob-gyn hospitals in
Vietnam, incomplete abortion was diagnosed by a trained
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administration was provided by a nurse midwife. Redu-
cing or replacing surgical management of incomplete
abortion with misoprostol as first line care could transfer
the majority of care from physicians to lower- or mid-
level providers such as nurses and nurse-midwives. This
task shifting, specifically in large urban hospitals, could
reduce costs and ease the burden on physicians with
heavy case loads. In other levels of the Vietnamese health
care system, such as the Commune level, where this
method could replace current recommended practice of
finger or ring forceps extraction with oxytocin 5 IU IM
and 1 amp ergometrine 0.2 mg IM at the Commune level
followed by transfer to higher level care, midwives are
trained to diagnose incomplete abortion clinically.
Vacuum aspiration and/or D&C are not permitted at
the Commune level. Furthermore, at the District level,
incomplete abortion is managed with either D&C or
aspiration; but not yet misoprostol. Incorporating mi-
soprostol at each of these levels of care would shift
the burden of care to lower cadres of providers and
help free up surgical wards and surgically skilled pro-
viders for other services.
Conclusion
From these data and given the consensus around the ef-
fectiveness of misoprostol for incomplete abortion care,
it seems timely that use of the drug for this indication
be widely expanded both throughout Vietnam and also
wherever access to incomplete abortion care, often re-
ferred to as PAC, is limited. Education and training on
incomplete abortion management with misoprostol
targeted towards a range of providers could provide an
easy-to-implement way to improve coverage and care
for this damaging women’s health problem.
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